Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program

• Abstract
• Lay summary
• Supplementary data

Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA^®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS

• Abstract
• Lay summary
• Supplementary data

Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program

• Abstracts
• Lay summary
• Supplementary data

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis Get access

Reply: In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis Get access

• Extract

Challenges in IBD Research 2024: Pragmatic Clinical Research

• Abstract
• Lay summary

Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States

Reply: Tofacitinib in Ulcerative Colitis: Beyond Biologics?

• Extract

Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort

• Abstract
• Lay summary
• Supplementary data

1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

• Extract

Use of Tramadol vs Traditional Opioids and Adverse Outcomes in Patients with Inflammatory Bowel Disease: A Danish Nationwide Cohort Study

• Abstract
• Supplementary data

Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study

• Extract

1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure

• Abstract
• Lay summary

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn’s-like Disease of the Pouch

• Abstract

Tofacitinib for the Treatment of Pouch-Related Disorders: A Case Series

Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

• Abstracts
• Supplementary data

Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders

• Extract
• Supplementary data

Infliximab De-escalation in Patients With Crohn’s Disease in Clinical Remission Is Safe and Well-tolerated

• Extract

Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis

• Extract
• Supplementary data